- Home
- OTEX vs IONS Comparison
OTEX vs IONS Comparison
Compare OTEX & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTEX
- IONS
- Stock Information
- Founded
- OTEX 1991
- IONS 1989
- Country
- OTEX Canada
- IONS United States
- Employees
- OTEX N/A
- IONS N/A
- Industry
- OTEX EDP Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- OTEX Technology
- IONS Health Care
- Exchange
- OTEX Nasdaq
- IONS Nasdaq
- Market Cap
- OTEX 6.6B
- IONS 6.8B
- IPO Year
- OTEX 1998
- IONS 1991
- Fundamental
- Price
- OTEX $29.87
- IONS $42.07
- Analyst Decision
- OTEX Hold
- IONS Buy
- Analyst Count
- OTEX 7
- IONS 15
- Target Price
- OTEX $30.86
- IONS $57.13
- AVG Volume (30 Days)
- OTEX 1.1M
- IONS 2.0M
- Earning Date
- OTEX 08-07-2025
- IONS 07-30-2025
- Dividend Yield
- OTEX 3.52%
- IONS N/A
- EPS Growth
- OTEX 295.06
- IONS N/A
- EPS
- OTEX 2.45
- IONS N/A
- Revenue
- OTEX $5,220,017,000.00
- IONS $717,253,000.00
- Revenue This Year
- OTEX N/A
- IONS $9.08
- Revenue Next Year
- OTEX $0.88
- IONS $14.72
- P/E Ratio
- OTEX $12.19
- IONS N/A
- Revenue Growth
- OTEX N/A
- IONS N/A
- 52 Week Low
- OTEX $22.79
- IONS $23.95
- 52 Week High
- OTEX $34.20
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- OTEX 60.39
- IONS 58.94
- Support Level
- OTEX $27.79
- IONS $41.25
- Resistance Level
- OTEX $30.27
- IONS $42.58
- Average True Range (ATR)
- OTEX 0.68
- IONS 1.42
- MACD
- OTEX -0.01
- IONS -0.30
- Stochastic Oscillator
- OTEX 83.87
- IONS 47.79
About OTEX Open Text Corporation
Open Text Corp is engaged in the design, development, marketing, and sale of Information Management software and solutions. Its software allows clients to archive, aggregate, retrieve, and search unstructured information (such as documents, e-mail, and presentations). Its platform and services provide secure and scalable solutions for enterprises, SMBs, governments, and consumers around the world. The company's solutions are marketed and delivered on the OpenText Cloud Platform, which is a comprehensive Information Management platform consisting of six business clouds; Content Cloud, Cybersecurity Cloud, Application Automation Cloud, Business Network Cloud, IT Operations Management Cloud, and Analytics Cloud. Geographically, it derives maximum revenue from the United States.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.